Edison Organics Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.10 M
as on 02-12-2024
- Paid Up Capital ₹ 2.10 M
as on 02-12-2024
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -1.74%
(FY 2022)
- Profit 16.22%
(FY 2022)
- Ebitda 13.43%
(FY 2022)
- Net Worth -29.12%
(FY 2022)
- Total Assets -25.91%
(FY 2022)
About Edison Organics Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.10 M and a paid-up capital of Rs 2.10 M, as per Ministry of Corporate Affairs (MCA) records.
Parminder Singh, Tulika Jain, and Aakash Jain serve as directors at the Company.
- CIN/LLPIN
U24132CH2012PTC033694
- Company No.
033694
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Edison Organics Pharmaceuticals Private Limited offer?
Edison Organics Pharmaceuticals Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Pain Reliever Gel, Antibiotic Tablets & Capsules, Cefuroxime Axetil Tablets, Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet, Cefixime Tablet.
Who are the key members and board of directors at Edison Organics Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parminder Singh  | Director | 09-Apr-2012 | Current |
| Tulika Jain | Director | 09-Dec-2019 | Current |
| Aakash Jain | Director | 09-Dec-2019 | Current |
Financial Performance of Edison Organics Pharmaceuticals.
Edison Organics Pharmaceuticals Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 1.74% decrease. The company also saw a substantial improvement in profitability, with a 16.22% increase in profit. The company's net worth observed a substantial decline by a decrease of 29.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edison Organics Pharmaceuticals?
In 2019, Edison Organics Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Promise Leasing And Finance Private LimitedActive 27 years 9 months
Parminder Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Edison Organics Pharmaceuticals?
Unlock and access historical data on people associated with Edison Organics Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Edison Organics Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Edison Organics Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
